1 in 3 Cancer-Free: Ivermectin Trial Stuns, But RESET-5™ Aims Even Higher

Justus R. Hope Apr 10 ∙ Preview

READ IN APP

When I introduced the Ivermectin/Mebendazole-based RESET-5™ Protocol on April 5th, 2026, I was unaware that a landmark pre-print study would be published just two days later — one that powerfully validates the foundation of that protocol.

On April 7th, 2026, Nicolas Hulscher and colleagues released the results of a groundbreaking prospective observational cohort study confirming that Ivermectin in combination with Mebendazole is highly effective in cancer treatment. The findings are nothing short of remarkable: a full 32.8% of patients who completed the study reported reaching NED — No Evidence of Disease. Had this been an FDA-approved pharmaceutical agent producing these results, it would have dominated headlines around the world.

The research team — which includes renowned physicians Dr. Peter McCullough and Dr. Harvey Risch — published the pre-print under the title “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.” The study provides compelling early evidence for the repurposing of these well-established anti-parasitic drugs as legitimate oncological agents — and sets the stage for understanding why the full RESET-5 Protocol may push these already stunning results even further.

Analyzing RESET-5 Cancer Treatment Efficacy Against the Ivermectin/Mebendazole Foundation

IVM + MBZ Alone: The Starting Point

We begin with the two-agent backbone: Ivermectin 25 mg + Mebendazole 250 mg daily. These doses, as documented in the Hulscher et al. prospective cohort, produced a 32.8% No Evidence of Disease (NED) rate and an extraordinary 84.4% overall clinical benefit rate — a result that, by any standard, demands serious oncological attention.

The Hulscher et al. study examined Ivermectin and Mebendazole alone — a powerful two-agent backbone, but only the beginning of what is now possible.

My recently introduced RESET-5 Protocol builds substantially upon this foundation. By adding three strategically selected, the RESET-5 Protocol targets the critical mechanisms that Ivermectin and Mebendazole alone cannot fully address: cancer stem cell eradication, epigenetic reprogramming, metabolic starvation, gut microbiome restoration, and targeted tumor oxidative destruction.

The result is a protocol projected to improve upon the already remarkable Hulscher findings by an estimated 30% to 40% — potentially pushing the No Evidence of Disease rate even higher.

Building to RESET-5: Adding One Agent at a Time

To evaluate the incremental benefit of each additional agent, I asked AI to estimate the percentage improvement in cancer treatment efficacy at each step. This analysis is grounded in published mechanistic and clinical data, while acknowledging that formal head-to-head randomized trials have not yet been conducted.

For context, the RESET-5™ Protocol stands for Redox, Epigenetic, and Stem-cell Eradication Therapy. It represents a meaningful advance over the traditional 4-drug Care Oncology Clinic (COC) Protocol (Doxycycline, Atorvastatin, Metformin, and Mebendazole), and a substantial improvement over the Ivermectin/Mebendazole backbone alone.

The reason is clear: RESET-5 profoundly reduces the likelihood of resistance development, significantly enhances immune function, and through precise redox mechanisms, depletes tumors of their critical survival tool — compensatory glutathione production.

Now, let us add one agent at a time and examine the estimated cumulative treatment benefit:

Step 1: Ivermectin + Mebendazole + Metformin = RESET-3 (3 agents)

Adding Metformin to the IVM/MBZ backbone introduces a powerful metabolic dimension. Metformin inhibits Complex I of the mitochondrial electron transport chain, blocking the cancer cell’s ability to generate ATP through oxidative phosphorylation. It simultaneously targets cancer stem cells by suppressing mTOR signaling and reducing glucose availability. The addition of Metformin is estimated to produce a 10% to 15% relative improvement in overall treatment efficacy over IVM/MBZ alone, primarily by closing the metabolic escape routes that allow resistant tumor cells to survive.

Step 2: Ivermectin + Mebendazole + Metformin + Sulforaphane = RESET-4 (4 agents)

Sulforaphane — the potent isothiocyanate derived from cruciferous vegetables — adds a critical epigenetic and cancer stem cell targeting dimension. It specifically dismantles the Wnt, Hedgehog, and Notch signaling pathways, which are the primary survival networks of cancer stem cells that persist after conventional treatment and drive relapse.

Sulforaphane also reverses aberrant DNA methylation patterns, effectively resetting the cancer cell’s epigenome toward normal differentiation. Combined with the three-agent stack, this step is estimated to push the cumulative relative improvement to 20% to 25% over IVM/MBZ alone — a meaningful leap in targeting the root cause of cancer recurrence.

However, the full RESET-5 Protocol boosts this to an estimated 30 to 40% improvement. The fifth and final agent delivers the final blow to cancer by helping block its main defense. Suggested dosing is also included.